Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403475 | 1.00 | SRD5A1 (0.47) | SRD5A1SRD5A2 | |
| SCHEMBL13611360 | 1.00 | SRD5A1 (0.47) | SRD5A1SRD5A2 | |
| SCHEMBL3505704 | 1.00 | SRD5A1 (0.47) | SRD5A1SRD5A2 | |
| SCHEMBL14355645 | 1.00 | SRD5A1 (0.47) | SRD5A1SRD5A2 | |
| SCHEMBL14387406 | 1.00 | SRD5A1 (0.47) | SRD5A1SRD5A2 | |
| SCHEMBL13604090 | 0.88 | AKR1B10 (0.51) | SRD5A1SRD5A2 | |
| SCHEMBL13604095 | 0.88 | SRD5A1 (0.49) | SRD5A1SRD5A2 | |
| SCHEMBL13611356 | 0.88 | SRD5A1 (0.49) | SRD5A1SRD5A2 | |
| SCHEMBL4177936 | 0.82 | SRD5A1 (0.57) | SRD5A1SRD5A2 | |
| SCHEMBL4177942 | 0.82 | SRD5A1 (0.57) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960417-B1 | POLYMORPHS OF ANDROGEN RECEPTOR MODULATOR - (N-3H-IMIDAZO [4 , 5-B] PYRIDIN-2-YL-METHYL) -2-FLUORO-4-METHYL-3-OXO-4-AZA-ANDROST- 1-EN-17 . BETA . -CARBOXAMIDE | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-7696217-B2 | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7625920-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2009-03-26 | — | — | US | disclosed |
| US-20090048283-A1 | Salt of an androgen receptor modulator | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| EP-1960417-A1 | POLYMORPHS OF ANDROGEN RECEPTOR MODULATOR - (N-3H-IMIDAZO [4 , 5-B] PYRIDIN-2-YL-METHYL) -2-FLUORO-4-METHYL-3-OXO-4-AZA-ANDROST- 1-EN-17 . BETA . -CARBOXAMIDE | Merck & Co., Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7410977-B2 | Fluorinated 4-azasteroids as androgen receptor modulators | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1641535-A4 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| US-7365202-B2 | Polymorphs of an androgen receptor modulator | MERCK & CO., INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070243266-A1 | Fluorinated 4-Azasteroids as Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2007-10-18 | — | — | US | disclosed |
| US-20060287349-A1 | 17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2006-12-21 | — | — | US | disclosed |
| US-20060287326-A1 | 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-12-21 | — | — | US | disclosed |
| EP-1670483-A1 | 17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1641535-A2 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005105091-A1 | FLUORINATED 4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
| WO-2005025579-A1 | 17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005005380-A2 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| EP-1485095-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003077919-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | SRD5A1 8/4885SRD5A2 12/4885 |
| US-20060287326-A1 | 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators | AR, NR5A1, NR3C1 | SRD5A1 12/4885SRD5A2 19/4885 |
| US-20060287349-A1 | 17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | AR, SHBG, NR5A1 | SRD5A1 18/4885SRD5A2 21/4885 |
| US-20090048283-A1 | Salt of an androgen receptor modulator | AR, SHBG, FSHR | SRD5A1 29/4885SRD5A2 42/4885 |
| US-20070243266-A1 | Fluorinated 4-Azasteroids as Androgen Receptor Modulators | NR5A1, AR, SHBG | SRD5A1 15/4885SRD5A2 19/4885 |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | SRD5A1 8/4885SRD5A2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.